BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38668032)

  • 21. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
    Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
    Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy.
    Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2022 Sep; 42(9):4573-4580. PubMed ID: 36039432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
    Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
    Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
    Yoshida J; Ishikawa T; Doi T; Ota T; Yasuda T; Okayama T; Sakamoto N; Inoue K; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Naito Y; Itoh Y
    Med Oncol; 2019 May; 36(7):60. PubMed ID: 31134385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
    Khan M; Zhao Z; Arooj S; Fu Y; Liao G
    Front Immunol; 2020; 11():587460. PubMed ID: 33329567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
    Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
    Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
    Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
    Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
    Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
    Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
    Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
    Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.